MedTrace Logo

A Clinical Trial in Healthy Participants to Learn How Itraconazole Affects MK-2828 Levels and How MK-2828 Affects Midazolam Levels (MK-2828-007)

NCT07435194 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-03-25

No results posted yet for this study

Summary

The main goals of this study are:

* To learn what happens to one dose of MK-2828 in a healthy person's body over time when it is taken with itraconzole
* To learn what happens to one dose of midazolam in a healthy person's body over time when it is taken with MK-2828

Researchers want to learn if the levels of MK-2828 in the body are about the same when MK-2828 is taken with itraconazole as when it is taken alone. They also want to know if taking MK-2828 more than once affects how much midazolam is in the body after a single dose.

Conditions

  • Healthy

Interventions

DRUG

MK-2828

Administered orally as capsule

DRUG

Itraconazole

Administered orally as syrup

DRUG

Midazolam

Administered orally as syrup

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
24 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2026-08-12
Completion
2026-08-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07435194 on ClinicalTrials.gov